HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial ...
HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a cl...
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international ...
HIGHLIGHTS * Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFI...